Table 1.
Baseline Characteristics of All Patients
| Total (n=27) | Combination Group (n=14) | Monotherapy Group (n=13) | P value | |
|---|---|---|---|---|
| Age (years; n, %), ≤60/>60 | 13 (48.15)/14 (51.85) | 6 (42.86)/8 (57.14) | 8 (61.54)/5 (38.46) | 0.280 |
| Gender (n, %), male/female | 21 (77.78)/6 (21.4) | 10 (71.43)/4 (28.57) | 11 (84.62)/2 (15.38) | 0.362 |
| Height (cm), Mean±SD | 168.15±6.78 | 167.35±2.09 | 169.00±1.56 | 0.540 |
| Body weight (kg), Mean±SD | 64.31±11.00 | 65.54±3.52 | 63.00±2.32 | 0.560 |
| Tumor size (cm), Mean±SD | 8.21±5.85 | 8.97±1.03 | 7.41±2.27 | 0.517 |
| Drinking history (n, %) | 3 (11.11) | 1 (7.14) | 2 (15.38) | 0.471 |
| AFP (n, %), ≤400/>400 | 14 (51.85)/13 (48.15) | 6 (42.86)/8 (57.14) | 8 (61.54)/5 (38.46) | 0.280 |
| Extrahepatic metastasis (n, %) | 17 (62.96) | 8 (57.14) | 9 (69.23) | 0.402 |
| Hepatic cirrhosis (n, %) | 23 (85.19) | 13 (92.86) | 10 (76.92) | 0.269 |
| Hepatitis (n, %) | ||||
| None | 2 (7.41) | 1 (7.14) | 1 (7.69) | 0.741 |
| B | 22 (81.48) | 11 (78.57) | 11 (84.62) | 0.538 |
| C | 3 (11.11) | 2 (14.29) | 1 (7.69) | 0.529 |
| Child-Pugh class (n, %) | 0.188 | |||
| A | 16 (59.26) | 9 (64.29) | 7 (53.85) | |
| B | 8 (29.63) | 5 (35.71) | 3 (23.08) | |
| C | 3 (11.11) | 0 | 3 (23.08) | |
| Previous therapy (n, %) | ||||
| Surgery | 5 (18.52) | 2 (14.29) | 3 (23.08) | 0.455 |
| Radiofrequency ablation | 8 (29.63) | 5 (35.71) | 3 (23.08) | 0.385 |
| TACE | 18 (66.67) | 8 (57.14) | 10 (76.92) | 0.279 |
| Chemotherapy | 3 (11.11) | 1 (7.14) | 2 (15.38) | 0.730 |
| Radiotherapy | 6 (22.22) | 4 (28.57) | 2 (15.38) | 0.048 |
| Immunotherapy | 12 (44.44) | 11 (78.57) | 1 (7.69) | 0.000 |
| Targeted therapy | 18 (66.67) | 10 (71.43) | 8 (61.54) | 0.445 |
| Antiviral therapy | 22 (81.48) | 11 (78.57) | 11 (84.62) | 0.538 |
| Traditional Chinese medicine | 24 (88.89) | 12 (85.71) | 12 (92.31) | 0.529 |
| BCLC stage (n, %) | 0.452 | |||
| B | 5 (18.52) | 3 (21.43) | 2 (15.38) | |
| C | 15 (55.56) | 9 (64.29) | 6 (46.15) | |
| D | 7 (25.93) | 2 (14.29) | 5 (38.46) | |
| CNLC stage (n, %) | 0.193 | |||
| II | 5 (18.52) | 2 (14.29) | 3 (23.08) | |
| III | 15 (55.56) | 10 (71.43) | 5 (38.46) | |
| IV | 7 (25.93) | 2 (14.29) | 5 (38.46) |
Abbreviations: AFP, alpha-fetoprotein; TACE, transhepatic arterial chemotherapy and embolization; BCLC, Barcelona Clinic Liver Cancer; CNLC, China Liver Cancer Staging.